Navigation Links
The Global Active Pharmaceutical Ingredients (API) Market: A Frost & Sullivan Briefing on Changing Dynamics
Date:5/4/2009

sday, 6th May 2009, which will provide industry participants an outlook of the Global Active Pharmaceutical Ingredients (API) Market. To participate, please email Katja Feick at katja.feick@frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. Upon receipt of the above information, a registration link will be emailed to you.

GIL 2009: Europe

Frost & Sullivan has expanded its flagship Global Congress on Corporate Growth - GIL Global - into several major cities around the world including London. For the first time ever in Europe, Frost & Sullivan will be hosting the Growth, Innovation and Leadership Congress 'GIL 2009: Europe' on 19-20 May, at the Sofitel St James in London. GIL Global is the industry's only event designed to support senior executives in their efforts to achieve sustainable, top-line growth. To register, obtain a programme agenda, explore sponsorship opportunities, or attend as a member of the media for GIL 2009: Europe, please contact Katja Feick, Corporate Communications Europe, at katja.feick@frost.com. One-on-One interviews with Frost & Sullivan senior growth consultants are also being scheduled.

For more information you can also visit http://www.frost.com/gilglobal

About Frost & Sullivan:

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and G
'/>"/>

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Resonant Medical Expands Sales Organization with Appointment of Vice President of Global Sales and Marketing
2. Matt Bars, a Global Expert in Smoking Cessation, Joins Next Safety as Chairman
3. Akaza Research to Present OpenClinica at ACRP Global Conference & Exhibition
4. Bayer CropScience Donates $1.1 Million to United Fresh Research & Education Foundation to Create the Center for Global Produce Sustainability
5. Setting the Benchmark for Winery Tasting Room Research: An Emerging Region Gets a Global Perspective
6. TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009
7. DuPont Leader: Agriculture is Up to Global Productivity Challenge
8. ACM Global Central Lab Announces Partnership with Chindexs United Family Hospitals in China
9. Global Aviation Summit Explores Low-Carbon Flight
10. Global Med Technologies(R) Licenses 90th Site in the Southeastern U.S.
11. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Robert Harman, ... Veterinary Medicine company, is proud to announce the relaunch of ... launching with a new series called “ What are Stem ... give an honest and straightforward foundation in the basics of ... educated decision on the right type of treatment when considering ...
(Date:7/10/2014)... POINT, Ind. , July 10, 2014 ... expanded its use of capnography for respiratory ... growing group of healthcare leaders in embracing ... measures how effectively patients are breathing and ... depression occurs. By measuring the amount of ...
(Date:7/10/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/s3bqj2/photonic ... "International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, ... report to their offering. ... photonic integration traces its roots in the latter ... photonic integration went unexplored and unfulfilled for several ...
(Date:7/10/2014)... microscopic polymer light resonators that expand in the ... Photonics Laboratory have developed new optical sensors with ... sensors are ideal for detecting trace gas concentrations ... nature, and immunity to electromagnetic interference. , Although ... the MIT team conceived an extremely sensitive, compact ...
Breaking Biology Technology:Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Swell new sensors 2
... 22 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. ("China ... develops, manufactures, and markets specialty pharmaceutical products in ... completed Phase I clinical trials of its novel ... to be the most widely prescribed class of ...
... SAN DIEGO, Sept. 22 Marshall Edwards, Inc. (Nasdaq: ... development of novel anti-cancer therapeutics, announced today that Daniel P. ... update on Marshall Edwards and its novel oncology programs at ... beginning at 4:30 p.m. EDT from the New York Palace ...
... Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to... -- HOERSHOLM, Denmark and SAN DIEGO, Sept. ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
Cached Biology Technology:China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 2China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 3China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 4Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 2Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 3Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 4Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 5Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 6Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 7Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 8Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 9Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 10
(Date:7/11/2014)... let nerve cells send out electrical signals, Johns Hopkins ... that may offer a new way to protect crops ... way. , Their findingthat naturally occurring insect toxins ... a closely related onesuggests that insecticides can be designed ... bees. A summary of the research, led by Frank ...
(Date:7/10/2014)... BEDFORD, Mass. , June 30, 2014  Aware, ... of biometrics software and services, previously announced on June ... a special cash dividend of $1.75 per share, or ... record date of July 10, 2014 and a payment ... notified by NASDAQ that it had set an ex-dividend ...
(Date:7/10/2014)... According to the new market research report, ... (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application (Mobile Devices, ... and Geography - Global Trends & Forecasts to 2014 ... Market is projected to cross $14.35 Billion by 2020, ... to 2020. Browse more than 78 market ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... Scientists have found that a large proportion of infants ... disease. The disease is the most prevalent acute wheezing ... admission to hospital in the first year of life in ... admitted to hospital for bronchiolitis - needing oxygen and help ...
... from small rings of naturally occurring plant DNA can ... embryonic plants where they are expressed, duplicated as plant ... -- a long-term goal for those interested in improving ... issue of PLoS-Genetics, a team of academic and commercial ...
... Research Hospital have identified the cell that gives rise to ... growth and development. The finding suggests for the first time ... induce fully developed neurons to multiply and coax the injured ... work appears in the Oct. 19 issue of the journal ...
Cached Biology News:Scientists find predisposition to bronchiolitis in some babies 2Transgenics transformed 2Transgenics transformed 3St. Jude identifies the specific cell that causes eye cancer, disproving long-held theory 2St. Jude identifies the specific cell that causes eye cancer, disproving long-held theory 3
... The Cetac Ultrasonic Nebulizers are available in two ... difference between these two models is that the ... to create a drier aerosol for improved detection ... detection limits for a range of elements by ...
...
... A-type ribonucleases Product Description: ,QIAGEN RNase Inhibitor ... binds noncovalently and inactivates a variety of ... It does not interfere with RNase T1, ... RNase Inhibitor inhibits greater than 90% of ...
...
Biology Products: